Suppr超能文献

叠氮基混合胺铂(IV)抗癌配合物可被可见光激活,形成新型 DNA 加合物。

Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts.

机构信息

Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK.

出版信息

Chemistry. 2013 Jul 15;19(29):9578-91. doi: 10.1002/chem.201300374. Epub 2013 Jun 3.

Abstract

Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from problems of resistance and side-effects. Photoactivatable Pt(IV) prodrugs offer the potential of targeted drug release and new mechanisms of action. We report the synthesis, X-ray crystallographic and spectroscopic properties of photoactivatable diazido complexes trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)] (1; MA=methylamine, Py=pyridine) and trans,trans,trans-[Pt(N3)2(OH)2(MA)(Tz)] (2; Tz=thiazole), and interpret their photophysical properties by TD-DFT modelling. The orientation of the azido groups is highly dependent on H bonding and crystal packing, as shown by polymorphs 1p and 1q. Complexes 1 and 2 are stable in the dark towards hydrolysis and glutathione reduction, but undergo rapid photoreduction with UVA or blue light with minimal amine photodissociation. They are over an order of magnitude more potent towards HaCaT keratinocytes, A2780 ovarian, and OE19 oesophageal carcinoma cells than cisplatin and show particular potency towards cisplatin-resistant human ovarian cancer cells (A2780cis). Analysis of binding to calf-thymus (CT), plasmids, oligonucleotide DNA and individual nucleotides reveals that photoactivated 1 and 2 form both mono- and bifunctional DNA lesions, with preference for G and C, similar to transplatin, but with significantly larger unwinding angles and a higher percentage of interstrand cross-links, with evidence for DNA strand cross-linking further supported by a comet assay. DNA lesions of 1 and 2 on a 50 bp duplex were not recognised by HMGB1 protein, in contrast to cisplatin-type lesions. The photo-induced platination reactions of DNA by 1 and 2 show similarities with the products of the dark reactions of the Pt(II) compounds trans-[PtCl2(MA)(Py)] (5) and trans-[PtCl2(MA)(Tz)] (6). Following photoactivation, complex 2 reacted most rapidly with CT DNA, followed by 1, whereas the dark reactions of 5 and 6 with DNA were comparatively slow. Complexes 1 and 2 can therefore give rapid potent photocytotoxicity and novel DNA lesions in cancer cells, with no activity in the absence of irradiation.

摘要

铂二氨络合物,如顺铂,是成功的抗癌药物,但存在耐药性和副作用的问题。光活化的 Pt(IV)前药提供了靶向药物释放和新的作用机制的潜力。我们报告了光活化叠氮化物配合物 trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)](1;MA=甲胺,Py=吡啶)和 trans,trans,trans-[Pt(N3)2(OH)2(MA)(Tz)](2;Tz=噻唑)的合成、X 射线晶体学和光谱性质,并通过 TD-DFT 建模解释其光物理性质。叠氮基团的取向高度依赖于氢键和晶体堆积,这在多晶型体 1p 和 1q 中得到了证明。配合物 1 和 2在暗处对水解和谷胱甘肽还原稳定,但在 UVA 或蓝光照射下会迅速光还原,几乎没有胺光解。它们对 HaCaT 角质形成细胞、A2780 卵巢和 OE19 食管癌细胞的活性比顺铂高一个数量级,并且对顺铂耐药的人卵巢癌细胞(A2780cis)表现出特别的活性。与小牛胸腺(CT)、质粒、寡核苷酸 DNA 和单个核苷酸结合的分析表明,光激活的 1 和 2 形成单功能和双功能 DNA 损伤,优先与 G 和 C 结合,与顺铂相似,但解旋角度更大,并且有更高比例的链间交联,彗星试验进一步证明了 DNA 链交联的存在。1 和 2 在 50bp 双链体上的 DNA 损伤未被 HMGB1 蛋白识别,与顺铂型损伤形成对比。1 和 2 对 DNA 的光诱导的铂化反应与 Pt(II)化合物 trans-[PtCl2(MA)(Py)](5)和 trans-[PtCl2(MA)(Tz)](6)的暗反应产物相似。光激活后,2 与 CT DNA 反应最快,其次是 1,而 5 和 6 与 DNA 的暗反应则相对较慢。因此,1 和 2 可以在没有照射的情况下迅速产生有效的光细胞毒性和癌细胞中的新型 DNA 损伤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b78/4280898/354032becd85/chem0019-9578-f14.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验